Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 4
2006 7
2007 9
2008 9
2009 9
2010 6
2011 16
2012 19
2013 15
2014 22
2015 22
2016 27
2017 17
2018 14
2019 13
2020 16
2021 19
2022 16
2023 16
2024 12
2025 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Sinn DH, Kang D, Guallar E, Cho J, Gwak GY. Sinn DH, et al. Among authors: gwak gy. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2435-2436. doi: 10.1016/j.cgh.2022.11.035. Epub 2022 Dec 9. Clin Gastroenterol Hepatol. 2023. PMID: 36503169 No abstract available.
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4.
Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. Dapito DH, et al. Among authors: gwak gy. Cancer Cell. 2012 Apr 17;21(4):504-16. doi: 10.1016/j.ccr.2012.02.007. Cancer Cell. 2012. PMID: 22516259 Free PMC article.
Reply.
Sinn DH, Kang D, Guallar E, Cho J, Gwak GY. Sinn DH, et al. Among authors: gwak gy. Hepatology. 2022 Dec;76(6):E121-E122. doi: 10.1002/hep.32678. Epub 2022 Aug 9. Hepatology. 2022. PMID: 35862461 No abstract available.
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY. Hong JY, et al. Among authors: gwak gy. Genome Med. 2022 Jan 6;14(1):1. doi: 10.1186/s13073-021-00995-8. Genome Med. 2022. PMID: 34986867 Free PMC article. Clinical Trial.
265 results